• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates

    3/26/24 3:08:06 PM ET
    $APCX
    $CDLX
    $GDS
    $MESO
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Technology
    Get the next $APCX alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday.

    The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03.

    Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1

     

    Leading and Lagging Sectors

     

    Consumer discretionary shares jumped by 0.6% on Monday.

    In trading on Monday, utilities shares fell by 1%.

     

    Top Headline

     

    TD SYNNEX Corporation (NYSE:SNX) reported better-than-expected first-quarter earnings.

    The company reported first quarter adjusted earnings per share of $2.99, beating the street view of $2.84. The company reported quarterly revenue of $13.975 billion, missing the analyst view of $14.357 billion.

     

    Equities Trading UP

     

    Stoke Therapeutics, Inc. (NASDAQ:STOK) shares shot up 72% to $11.19 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.

    Shares of Mesoblast Ltd (NASDAQ:MESO) got a boost, surging 66% to $3.6420 after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.

    OpGen, Inc. (NASDAQ:OPGN) shares were also up, gaining 47% to $0.6972 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million.

     

    Equities Trading DOWN

     

    Cardlytics Inc (NASDAQ:CDLX) shares dropped 33% to $13.65 after the company announced a $150 million proposed convertible senior notes offering.

    Shares of GDS Holdings Ltd - ADR (NASDAQ:GDS) were down 26% to $6.20 after the company reported fourth-quarter results, disclosed equity raise and new CEO for its international business.

    AppTech Payments Corp. (NASDAQ:APCX) was down, falling 42% to $0.9548 after the company priced its 2 million share offering at $1 per share.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 5% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded down 0.5% to $81.53 while gold traded up 0.1% at $2,178.70.

    Silver traded down 1% to $24.635 on Monday, while copper fell 0.2% to $4.0085.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 rose 0.24%, London’s FTSE 100 rose 0.17% while Spain’s IBEX 35 Index rose 0.36% The German DAX rose 0.67% French CAC 40 rose 0.41% while Italy’s FTSE MIB Index rose 0.14%.

    The GfK Consumer Climate Indicator for Germany rose to -27.4 heading into April compared to a revised reading of -28.8 in the prior period. Spanish economy grew 0.6% in the fourth quarter, compared to a 0.4% increase in the prior period.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 falling 0.04%, Hong Kong’s Hang Seng Index gaining 0.88%, China’s Shanghai Composite Index gaining 0.17% and India’s S&P BSE Sensex falling 0.50%.

    Hong Kong’s trade deficit narrowed to $41.7 billion in February versus a $45.4 billion gap recorded in the year-ago period.

     

    Economics

     

    U.S. durable goods orders increased by 1.4% month-over-month in February versus a revised 6.9% decline in January.

    The S&P CoreLogic Case-Shiller 20-city home price index increased by 6.6% year-over-year in January compared to a 6.2% gain in the prior month.

    The FHFA house price index fell by 0.1% in January.

    The Dallas Fed general business activity index for Texas' service sector fell to a reading of -5.5 in March from -3.9 in February.

    Now Read This: How To Earn $500 A Month From Micron Technology Stock After Last Week's Strong Earnings

     

    Get the next $APCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APCX
    $CDLX
    $GDS
    $MESO

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    TD SYNNEX Corporation
    $SNX
    1/13/2026$180.00Buy
    Goldman
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    GDS Holdings Limited
    $GDS
    11/6/2025Outperform
    Macquarie
    GDS Holdings Limited
    $GDS
    8/12/2025$48.00Sector Perform → Outperform
    RBC Capital Mkts
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    More analyst ratings

    $APCX
    $CDLX
    $GDS
    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on TD Synnex with a new price target

    Goldman resumed coverage of TD Synnex with a rating of Buy and set a new price target of $180.00

    1/13/26 9:18:14 AM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APCX
    $CDLX
    $GDS
    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

    NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah. The study results showed that Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease (SR-aGvHD) irrespective whether used in children or adults, as second or third line, and in ruxolitinib naive or resistant patients.1 Ryoncil® is the

    2/11/26 6:27:47 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

    –Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life to be evaluated as secondary objectives– –ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in progressive and irreversible vision loss– Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Do

    2/11/26 7:30:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Sto

    2/4/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $APCX
    $CDLX
    $GDS
    $MESO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lord Albert L bought $52,132 worth of shares (120,000 units at $0.43), increasing direct ownership by 4% to 3,016,194 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    12/4/25 7:22:39 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Lord Albert L bought $23,347 worth of shares (57,500 units at $0.41), increasing direct ownership by 2% to 2,896,194 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    11/28/25 5:11:59 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $APCX
    $CDLX
    $GDS
    $MESO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Zammit Patrick sold $2,384,823 worth of shares (13,900 units at $171.57), decreasing direct ownership by 8% to 170,928 units (SEC Form 4)

    4 - TD SYNNEX CORP (0001177394) (Issuer)

    2/9/26 4:06:56 PM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Hume Richard T exercised 18,365 shares at a strike of $107.32 and sold $3,753,017 worth of shares (23,365 units at $160.63), decreasing direct ownership by 11% to 42,515 units (SEC Form 4)

    4 - TD SYNNEX CORP (0001177394) (Issuer)

    2/4/26 5:52:07 PM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Hume Richard T exercised 492 shares at a strike of $107.32 and sold $78,922 worth of shares (492 units at $160.41) (SEC Form 4)

    4 - TD SYNNEX CORP (0001177394) (Issuer)

    2/2/26 7:08:01 PM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    $APCX
    $CDLX
    $GDS
    $MESO
    SEC Filings

    View All

    SEC Form DEFA14A filed by TD SYNNEX Corporation

    DEFA14A - TD SYNNEX CORP (0001177394) (Filer)

    2/13/26 8:33:01 AM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form DEF 14A filed by TD SYNNEX Corporation

    DEF 14A - TD SYNNEX CORP (0001177394) (Filer)

    2/13/26 8:31:01 AM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    2/11/26 8:59:17 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APCX
    $CDLX
    $GDS
    $MESO
    Financials

    Live finance-specific insights

    View All

    GDS Announces Private Placement of US$300 Million convertible preferred shares to A Chinese Institutional Investor

    SHANGHAI, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:GDS, HKEX: 9698)), a leading developer and operator of high-performance data centers in China, today announced a private placement of US$300 million of Series B convertible preferred shares (the "convertible preferred shares") to Huatai Capital Investment Limited, a Chinese institutional investor (the "Private Placement"). GDS will use the proceeds from the private placement to fund expansion of its data center capacity and for general corporate purposes. The convertible preferred shares include the following key terms: During the first six years from their issuance da

    1/30/26 8:40:00 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    TD SYNNEX Reports Record Fiscal 2025 Fourth Quarter Results

    Revenue of $17.4 billion, an increase of 9.7% year over year and above the high end of our outlook. On a constant currency(1) basis, revenue increased by 7.5% year over year. Non-GAAP gross billings(1) of $24.3 billion, an increase of 14.7% year over year and above the high end of our outlook. On a constant currency(1) basis, non-GAAP gross billings(1) increased by 12.6% year over year. Diluted earnings per share ("EPS") of $3.04, and non-GAAP diluted EPS(1) of $3.83, an increase of 24.0% year over year. Cash provided by operations of $1.5 billion and free cash flow(1) of $1.4 billion. Returned $209 million to stockholders in the form of $173 million of share repurchases and $3

    1/8/26 7:00:00 AM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    TD SYNNEX to Announce Fiscal 2025 Full Year and Fourth Quarter Results on January 8, 2026

    TD SYNNEX (NYSE:SNX) today announced it will report its financial results for the fourth quarter and full year of fiscal 2025 before the U.S. market opens on Thursday, January 8, 2026. The Company will host a conference call at 6:00 a.m. PT / 9:00 a.m. ET that same day to discuss the results. Links to the live webcast of the conference call as well as the earnings materials will be available in the "Quarterly Results" section of the Company's website at https://ir.tdsynnex.com/ir-home/default.aspx starting at approximately 4:00 a.m. PT / 7:00 a.m. ET. A replay of the webcast will be available following the call. About TD SYNNEX TD SYNNEX (NYSE:SNX) is a leading global distributor and solu

    12/11/25 4:05:00 PM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    $APCX
    $CDLX
    $GDS
    $MESO
    Leadership Updates

    Live Leadership Updates

    View All

    Hyve Solutions Announces Leadership Transition

    Jerry Kagele Named President; Steve Ichinaga Transitions to Advisory Role After 15 Years Leading Hyperscale Infrastructure Pioneer Hyve Solutions Corporation, a wholly owned subsidiary of TD SYNNEX Corporation (NYSE:SNX) and a leader in the design to worldwide deployment of hyperscale digital infrastructures, today announced that Jerry Kagele has been named President of Hyve Solutions. Kagele succeeds Steve Ichinaga, who is transitioning to an advisory role after four decades of service at TD SYNNEX, including the last 15 years as the founding executive of Hyve Solutions. This planned leadership transition positions the company for continued growth and seamless operational continuity. I

    1/27/26 5:00:00 PM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Helios Technologies Fortifies Finance and Accounting Leadership Team

    Michael Connaway to join as Chief Financial Officer in October 2025 Jeremy Evans promoted to Chief Accounting Officer effective September 1, 2025 Helios Technologies, Inc. (NYSE:HLIO) ("Helios" or the "Company"), a global leader in highly engineered motion control and electronic controls technology for diverse end markets, announced today that Michael Connaway will be joining the Company as Chief Financial Officer and Jeremy Evans, Helios' Corporate Controller, will be promoted to the expanded role of Chief Accounting Officer. Mr. Connaway will assume the role when he joins the Company in October with the specific date to be determined. Effective with the appointment of Mr. Connaway,

    8/28/25 9:00:00 AM ET
    $AVNW
    $HLIO
    $SNX
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Metal Fabrications
    Industrials

    $APCX
    $CDLX
    $GDS
    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care